ViroSpot microneutralization assay for antigenic characterization of human influenza viruses

Vaccine

Volumn 35, Issue 1, 2017, Pages 46-52

  van Baalen, Carel A ^a   Jeeninga, Rienk E ^a   Penders, Germaine H W M ^a   van Gent, Brenda ^a   van Beek, Ruud ^b,c   Koopmans, Marion P G ^b,c   Rimmelzwaan, Guus F ^b,c  

^a ViroClinics Biosciences BV   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c WHO Natl Influenza Centre (NIC)   (Netherlands)

Author keywords

Antigenic characterization; Influenza A virus, H3N2 subtype; Neutralization tests

Indexed keywords

ANIMAL CELL; ANTIGENICITY; ARTICLE; AUTOMATION; CONTROLLED STUDY; HEMAGGLUTINATION INHIBITION TEST; IMMUNOHISTOCHEMISTRY; INFLUENZA A VIRUS (H3N2); INFLUENZA VIRUS; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; VIROSPOT MICRONEUTRALIZATION ASSAY; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; VIRUS TRANSMISSION; CLASSIFICATION; EVALUATION STUDY; HUMAN; IMMUNOLOGY; INFLUENZA; ISOLATION AND PURIFICATION; ORTHOMYXOVIRIDAE; PROCEDURES; SERODIAGNOSIS; VIROLOGY;

VIRUS ANTIGEN;

ANTIGENS, VIRAL; HUMANS; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE;

EID: 84999837845     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.060     Document Type: Article

References (17)

1. [1] Smith, D.J., Lapedes, A.S., de Jong, J.C., Bestebroer, T.M., Rimmelzwaan, G.F., Osterhaus, A.D., et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305:5682 (2004), 371–376.
2. [2] van de Sandt, C.E., Bodewes, R., Rimmelzwaan, G.F., de Vries, R.D., Influenza B viruses: not to be discounted. Future Microbiol 10:9 (2015), 1447–1465.
3. [3] Flannery, B., Clippard, J., Zimmerman, R.K., Nowalk, M.P., Jackson, M.L., Jackson, L.A., et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep 64:1 (2015), 10–15.
4. [4] Pebody, R., Warburton, F., Andrews, N., Ellis, J., von Wissmann, B., Robertson, C., et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill, 20(36), 2015.
5. [5] Skowronski, D.M., Chambers, C., Sabaiduc, S., De Serres, G., Dickinson, J.A., Winter, A.L., et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Euro Surveill, 20(4), 2015.
6. [6] Koel, B.F., Burke, D.F., Bestebroer, T.M., van der Vliet, S., Zondag, G.C., Vervaet, G., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342:6161 (2013), 976–979.
7. [7] Lin, Y.P., Gregory, V., Collins, P., Kloess, J., Wharton, S., Cattle, N., et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?. J Virol 84:13 (2010), 6769–6781.
8. [8] Lin, Y., Gu, Y., Wharton, S.A., Whittaker, L., Gregory, V., Li, X., et al. Optimization of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses. Influenza Other Respir Viruses 9:6 (2015), 331–340.
9. [9] WHO, Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. Weekly Epidemiol Rec 90:41 (2015), 545–560.
10. [10] Rowe, T., Abernathy, R.A., Hu-Primmer, J., Thompson, W.W., Lu, X., Lim, W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37:4 (1999), 937–943.
11. [11] WHO. Manual for the laboratory diagnosis and virological surveillance of influenza. WHO Geneva; 2011.
12. [12] van Baalen, C.A., Els, C., Sprong, L., van Beek, R., van der Vries, E., Osterhaus, A.D., et al. Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture. J Clin Microbiol 52:5 (2014), 1672–1677.
13. [13] Isaacs, A., Gledhill, A.W., Andrewes, C.H., Influenza A viruses; laboratory studies, with special reference to European outbreak of 1950-1. Bull World Health Organ 6:3 (1952), 287–315.
14. [14] Westgeest, K.B., Bestebroer, T.M., Spronken, M.I., Gao, J., Couzens, L., Osterhaus, A.D., et al. Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. J Virol Methods 217 (2015), 55–63.
15. [15] Matrosovich, M., Matrosovich, T., Garten, W., Klenk, H.D., New low-viscosity overlay medium for viral plaque assays. Virol J, 3, 2006, 63.
16. [16] Chambers, B.S., Parkhouse, K., Ross, T.M., Alby, K., Hensley, S.E., Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep 12:1 (2015), 1–6.
17. [17] Ampofo, W.K., Azziz-Baumgartner, E., Bashir, U., Cox, N.J., Fasce, R., Giovanni, M., et al. Strengthening the influenza vaccine virus selection and development process: report of the 3rd WHO informal consultation for improving influenza vaccine virus selection held at WHO headquarters, Geneva, Switzerland, 1–3 April 2014. Vaccine 33:36 (2015), 4368–4382.